Advertisement

Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)

Published:September 30, 2022DOI:https://doi.org/10.1016/j.ejca.2022.09.007

      Highlights

      • This report covers 1520 deaths occurring after osteosarcoma.
      • Deaths arose after a median of about two years, but very late events occurred.
      • Most patients died without ever achieving a remission or with multiple recurrences.
      • Almost ten percent succumbed to other known causes than osteosarcoma itself.
      • Infections, secondary malignancies, and perioperative complications were frequent.

      Abstract

      Purpose

      Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death.

      Methods

      The database of the Cooperative Osteosarcoma Study Group COSS (1980-03/31/2021; 4475 registered high-grade central osteosarcoma patients) was searched deaths from any cause. Affected patients were analyzed for demographic and baseline variables and disease-status at the time of demise. Deaths from causes other than osteosarcoma were analyzed in detail.

      Results

      A total of 1520 deceased patients were identified (median age (range) at osteosarcoma diagnosis 16 (2–78) years; 908 (59.7%) male, 612 (40.3%) female; primary tumor: extremities 1263 (83.1%), trunk 208 (13.7%), craniofacial 47 (3.1%) (site unknown 2); metastases at registration: absent 1.051 (69.1%), present 466 (30.7%) (3 no data). The median time from diagnosis to death was 2.22 (0.08–32.02) years. 1286 (84.6%) patients succumbed to osteosarcoma (370 without achieving complete remission, 488 first, 428 more than one recurrences), 146 (9.6%) to other, 88 (5.8%) to unknown causes. Chemotherapy-related infections (40), secondary malignancies (39), and perioperative complications (19) were among the most frequent potentially treatment-related causes, and high-dose methotrexate (19), doxorubicin (17), and ifosfamide (15) were the drugs most commonly held responsible. Patients with unknown causes of death had an unusually long median follow-up.

      Conclusion

      The major cause of death of patients after osteosarcoma is this malignancy, mostly from one of its multiple relapses. However, almost 10% of fatalities are due to other documented causes. Some of these deaths may be preventable with the knowledge gained from comprehensive analyses such as this.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Meltzer P.S.
        • Helman L.J.
        New horizons in the treatment of osteosarcoma.
        N Engl J Med. 2021 Nov 25; 385: 2066-2076https://doi.org/10.1056/NEJMra2103423
        • Bielack S.
        • Cable M.G.
        • Gorlick R.
        • Hecker-Nolting S.
        • Kager L.
        • Marina N.
        • et al.
        Osteosarcoma – approach to therapy.
        in: Arndt C.A.S. Sarcomas of bone and soft tissues in children and adolescents. Pediatr Oncol, 2021: 91-109 (10.107/978-3-030-51160-9_8)
        • Bielack S.
        • Jürgens H.
        • Jundt G.
        • Kevric M.
        • Kühne T.
        • Reichardt P.
        • et al.
        Osteosarcoma: the COSS experience.
        Cancer Treat Res. 2009; 152: 289-308https://doi.org/10.1007/978-1-4419-0284-9_15
        • Ferrari S.
        • Bielack S.S.
        • Smeland S.
        • Longhi A.
        • Egerer G.
        • Sundby Hall K.
        • et al.
        A European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma.
        Tumori. 2018 Jan-Feb; 104: 30-36https://doi.org/10.5301/tj.5000696
        • Smeland S.
        • Bielack S.S.
        • Whelan J.
        • Bernstein M.
        • Hogendoorn P.
        • Krailo M.D.
        • et al.
        Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
        Eur J Cancer. 2019 Mar; 109: 36-50https://doi.org/10.1016/j.ejca.2018.11.027
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Bielack S.S.
        • Kempf-Bielack B.
        • Delling G.
        • Exner G.U.
        • Flege S.
        • Helmke K.
        • et al.
        Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.
        J Clin Oncol. 2002 Feb 1; 20: 776-790https://doi.org/10.1200/JCO.2002.20.3.776
        • Widemann B.C.
        • Adamson P.C.
        Understanding and managing methotrexate nephrotoxicity.
        Oncologist. 2006 Jun; 11: 694-703https://doi.org/10.1634/theoncologist.11-6-694
        • Bhatia S.
        Therapy-related myelodysplasia and acute myeloid leukemia.
        Semin Oncol. 2013 Dec; 40: 666-675https://doi.org/10.1053/j.seminoncol.2013.09.013
        • Raj S.
        • Franco V.I.
        • Lipshultz S.E.
        Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.
        Curr Treat Options Cardiovasc Med. 2014 Jun; 16: 315https://doi.org/10.1007/s11936-014-0315-4